Bayer said it expects to report lower earnings this year as it continues to work through a turnaround plan, but performance should improve from 2026.
The pharmaceutical and agricultural conglomerate said all three of its business units have attractive long-term prospects, but it must first steer them through a challenging period ahead before it can take advantage of any opportunities.
"It is the second year in Bayer's turnaround and will be the most difficult in terms of financial performance," the German company said Wednesday.
The year will be pivotal, Bayer said, as it also launched a five-year plan to improve earnings at its crop-science business.
The company expects to report earnings before interest, taxes, depreciation, amortization and special items--its closely watched profitability metric--this year of between 9.5 billion and 10 billion euros ($10.10 billion-$10.63 billion) on a currency-adjusted basis.
That would mark a decline from 10.12 billion euros in 2024.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.